ReferenceID 2581

Investigation on the antitumor effects of paeonol against renal cell carcinoma based on network pharmacology and experimental validation

J Ethnopharmacol

Ethnopharmacological relevance: Renal cell carcinoma (RCC) is the most common cancer of the urinary system, the current treatments for RCC are unsatisfactory. Paeonol is the main pharmacologically active ingredient of th

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final reference record.

Reference Id
2581
Evidence Id
19171
Core Evidence Id
19171
Source Reference Id
5162
Herb2 Reference Id
HBREF005959
Subject Paper Key
HBIN038627_34813895
Pubmed Id
34813895
Doi
10.1016/j.jep.2021.114857
Paper Title
Investigation on the antitumor effects of paeonol against renal cell carcinoma based on network pharmacology and experimental validation
Paper Abstract
Ethnopharmacological relevance: Renal cell carcinoma (RCC) is the most common cancer of the urinary system, the current treatments for RCC are unsatisfactory. Paeonol is the main pharmacologically active ingredient of the traditional Chinese medicine (TCM) moutan cortex (Paeonia suffruticosa Andrews) and Paeonia albiflora Pall, and has been used in TCM to treat various diseases including cancer. However, the underlying therapeutic mechanisms of paeonol in RCC have not been investigated yet. Aim of the study: This study aimed to explore the potential antitumor effects and mechanisms of paeonol on RCC based on network pharmacology and experimental validation. Materials and methods: Network pharmacological analysis was performed to predict the potential targets and mechanism of paeonol against RCC. The antitumor effects and the priority targets of paeonol against RCC were further assessed by in vitro experiments. Results: 104 intersection targets shared by paeonol and RCC were collected, 15 hub genes were obtained, among these genes, VEGFA expression was higher in RCC, and the higher expression of IL-6 or lower expression of AKT1, JUN, MAPK1, and MAPK8 were correlated to the shorter overall survival (OS) in RCC patients. GO and KEGG analyses suggested that the genes were mainly enriched in the positive regulation of cell death and apoptosis pathway. In vitro experiments showed that paeonol inhibited 786-O cell proliferation, migration, invasion, and promoted apoptosis. When 786-O cells were treated with paeonol, the expression of Bax increased while Bcl-2 and VEGFA decreased. Conclusion: The present study demonstrated that paeonol might play an essential role in RCC by regulating cell proliferation, apoptosis, metastasis, and invasion through the Bcl-2/Bax signaling pathway and VEGFA, providing a theoretical and experimental scientific basis for future investigations of the antitumor effects of paeonol against RCC.
Journal
J Ethnopharmacol
Publish Year
2021
Experiment Subject
patient; 786-o cells
Experiment Type
Cell Experiment
Phenotype Related
Cancer; Renal Cell Carcinoma
Paper Title Cn
Paper Title En
Investigation on the antitumor effects of paeonol against renal cell carcinoma based on network pharmacology and experimental validation
Bilingual Status
semi_complete